## HECEIVED CENTRAL FAX CENTER

JAN 0 8 2008 CASE 4-32702A

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Cindy Klepacky

Circly Kleparky

1/8/08 Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1634

KUDARAVALLI ET AL.

Examiner: Pohnert, Steven C

**APPLICATION NO: 10/529,613** 

FILED: MARCH 30, 2005

FOR: METHODS TO TREAT CHOLESTEROL ELEVATIONS DURING

**IMMUNOSUPPRESSANT THERAPY** 

MS: Petition

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

## PETITION TO REVIVE UNDER 37 CFR 1.137(b)

Sir:

Applicants respectfully request that the above-identified application be revived under the provisions of 37 CFR 1.137(b).

This application became abandoned for Applicant's failure to timely file a proper reply to the Office Action mailed on May 7, 2007.

In response to the Notice of Abandonment, Applicant's enclose a copy of

In accordance with 37 CFR 1.137(b)(2), the Commissioner is hereby authorized to charge the fee of \$1,500 required by 37 CFR 1.17(m) to Deposit Account No. 19-0134 in the name of Novartis. A duplicate copy of this Petition is also enclosed.

**Novartis** 

Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 778-9308

Date:

Dunfin

Leslie Fischer

Attorney for Applicants

Respectfully submitted,

Reg. No. 58,393

01/09/2008, SSESHET 00000014 190134 10529613

01 (FC:1453 1540.00 DA

ĖR

PTC/SB/64 (01-08)

Approved for use through 01/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persona are required to respond to a collection of information unloss it displays a valid OMB control number.

ABANDO	I FOR REVIVAL OF AN APPLICATION FOR NED UNINTENTIONALLY UNDER 37 CFR	R PATENT 1.137(b)	Docket Nur	nber (Optional) 4-32702
First named	inventor: Sridhar Kudaravalli			RECEIVED
Application No.: 10/529613		Art Unit: 1634	CI	ENTRÂL FAX CÊN
Filed: June 8,	2005	Examiner: Pohne	rt, Steven C	JAN 0 8 2008
Title: METHOD	OS TO PREDICT CHOLESTEROL ELEVATIONS DURING IMMUNO	OSUPPRESSANT TH	ERAPY	
Mail Stop Pe Commissione P.O. Box 145	er for Patents 50 /A 22313-1450			
ľ	NOTE: If information or assistance is needed in comp Information at (571) 272-3282.	leting this form, p	lease conta	ct Petitions
action by the	dentified application became abandoned for failure to United States Patent and Trademark Office. The date eriod set for reply in the office notice or action plus an	of abandonment	is the day a	fter the expiration
	APPLICANT HEREBY PETITIONS FOR REVIV	AL OF THIS APP	LICATION	
1	NOTE: A grantable petition requires the following items (1) Petition fee; (2) Reply and/or issue fee; (3) Terminal disclaimer with disclaimer fee - red filed before June 8, 1995; and for all design (4) Statement that the entire delay was uninten	quired for all utility	and plant a	pplications
<del></del>	entity-fee \$ (37 CFR 1.17(m)). Applicant cla than small entity – fee \$ <u>1540.00</u> (37 CFR 1.17		tatus. See 3	37 CFR 1.27,
2. Reply and/o A. T		1	type of rep	ly):
	has been filed previously onis enclosed herewith.	·		
В. Т	The issue fee and publication fee (if applicable) of \$ has been paid previously on is enclosed herewith.			
This collection of inf USPTO to process)	[Page 1 of 2] formation is required by 37 CFR 1.137(b). The information is required to a sm application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR	btein or retain a benefit	by the public wh	ich la to ille (and by the

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is eathnated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form analyr suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

01/09/2008 SSESHE1 00000014 10529613

01 FC:1453 1540.00 DA

PTQ/5B/64 (01-08) Approved for use through 01/31/2008. OMB 0851-0031
U.S. Pakent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 3. Terminal disclaimer with disclaimer fee Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required. A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ \_ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63). 4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional, [NOTE: The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D)).1 WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. Signature Date Lestie Fischer 58,393 Typed or printed name Registration Number, if applicable Novartis, One Health Plaza, East Hanover, NJ 07936-1080 862 778-9308 Address Telephone Number Address Enclosures: Fee Payment Reply Terminal Disclaimer Form Additional sheets containing statements establishing unintentional delay Other: Petition to expunde Information from an application CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)] I hereby certify that this correspondence is being: Deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at/(571) 273-8300. Cindy Klepack Typed or printed name of person signing certificate

[Page 2 of 2]